Of 16 HER2-negative breast cancer patients, our results showed that the changes in all 29 altered plasma metabolomes 2 weeks after completion of doxorubicin were significantly correlated with the changes in altered cardiac parameters (either LVEF, LF/HF ratio or plasma troponin I) three months after completion of doxorubicin treatment, as detailed in Fig. 7. This evidence concerns the gene ERBB2 and breast carcinoma.